| Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model E Spangenberg, PL Severson, LA Hohsfield, J Crapser, J Zhang, ... Nature communications 10 (1), 3758, 2019 | 582 | 2019 |
| Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor WD Tap, ZA Wainberg, SP Anthony, PN Ibrahim, C Zhang, JH Healey, ... New England Journal of Medicine 373 (5), 428-437, 2015 | 532 | 2015 |
| BRD4 profiling identifies critical chronic lymphocytic leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor HG Ozer, D El-Gamal, B Powell, ZA Hing, JS Blachly, B Harrington, ... Cancer discovery 8 (4), 458-477, 2018 | 117 | 2018 |
| Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors R Wesolowski, N Sharma, L Reebel, MB Rodal, A Peck, BL West, ... Therapeutic advances in medical oncology 11, 1758835919854238, 2019 | 104 | 2019 |
| Hypoxia perturbs aryl hydrocarbon receptor signaling and CYP1A1 expression induced by PCB 126 in human skin and liver-derived cell lines SU Vorrink, PL Severson, MV Kulak, BW Futscher, FE Domann Toxicology and applied pharmacology 274 (3), 408-416, 2014 | 88 | 2014 |
| Arsenic exposure induces the Warburg effect in cultured human cells F Zhao, P Severson, S Pacheco, BW Futscher, WT Klimecki Toxicology and applied pharmacology 271 (1), 72-77, 2013 | 73 | 2013 |
| Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease JD Clarke, P Novak, AD Lake, P Shipkova, N Aranibar, D Robertson, ... Digestive diseases and sciences 59, 365-374, 2014 | 58 | 2014 |
| Monomethylarsonous acid produces irreversible events resulting in malignant transformation of a human bladder cell line following 12 weeks of low-level exposure SM Wnek, TJ Jensen, PL Severson, BW Futscher, AJ Gandolfi Toxicological Sciences 116 (1), 44-57, 2010 | 58 | 2010 |
| Coordinate H3K9 and DNA methylation silencing of ZNFs in toxicant-induced malignant transformation PL Severson, EJ Tokar, L Vrba, MP Waalkes, BW Futscher Epigenetics 8 (10), 1080-1088, 2013 | 44 | 2013 |
| Exome-wide mutation profile in benzo [a] pyrene-derived post-stasis and immortal human mammary epithelial cells PL Severson, L Vrba, MR Stampfer, BW Futscher Mutation Research/Genetic Toxicology and Environmental Mutagenesis 775, 48-54, 2014 | 39 | 2014 |
| Agglomerates of aberrant DNA methylation are associated with toxicant-induced malignant transformation PL Severson, E Tokar, L Vrba, M Waalkes, B Futscher Epigenetics 7 (11), 1238-1248, 2012 | 39 | 2012 |
| A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia CC Smith, MJ Levis, O Frankfurt, JM Pagel, GJ Roboz, RM Stone, ... Blood advances 4 (8), 1711-1721, 2020 | 36 | 2020 |
| Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model. Nat Commun 10: 3758 E Spangenberg, PL Severson, LA Hohsfield, J Crapser, J Zhang, ... | 34 | 2019 |
| Phase ib/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors. A Patnaik, RD Carvajal, KM Komatsubara, CD Britten, R Wesolowski, ... Journal of Clinical Oncology 36 (15_suppl), 2550-2550, 2018 | 30 | 2018 |
| Association of combination of conformation-specific KIT inhibitors with clinical benefit in patients with refractory gastrointestinal stromal tumors: a phase 1b/2a … AJ Wagner, PL Severson, AF Shields, A Patnaik, R Chugh, G Tinoco, ... JAMA oncology 7 (9), 1343-1350, 2021 | 25 | 2021 |
| Results from phase I extension study assessing pexidartinib treatment in six cohorts with solid tumors including TGCT, and abnormal CSF1 transcripts in TGCT WD Tap, AS Singh, SP Anthony, M Sterba, C Zhang, JH Healey, ... Clinical Cancer Research 28 (2), 298-307, 2022 | 13 | 2022 |
| Cellular localization of kynurenine 3-monooxygenase in the brain: Challenging the dogma KV Sathyasaikumar, V Pérez de la Cruz, B Pineda, GI Vázquez Cervantes, ... Antioxidants 11 (2), 315, 2022 | 11 | 2022 |
| Interim results from a phase 1/2 precision medicine study of PLX8394-a next generation BRAF inhibitor F Janku, EJ Sherman, AR Parikh, LG Feun, F Tsai, E Allen, C Zhang, ... European Journal of Cancer 138, S2-S3, 2020 | 11 | 2020 |
| Phase 1/2 precision medicine study of the next-generation BRAF inhibitor PLX8394. F Janku, UN Vaishampayan, V Khemka, M Bhatty, EJ Sherman, J Tao, ... Journal of Clinical Oncology 36 (15_suppl), 2583-2583, 2018 | 11 | 2018 |
| A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in … AJ Wagner, WD Tap, AF Shields, A Patnaik, R Chugh, G Tinoco, ... Journal of clinical oncology 36 (15_suppl), 11509-11509, 2018 | 11 | 2018 |
